SAN 📈 Sanofi SA - Overview

Exchange: PA • Country: France • Currency: EUR • Type: Common Stock • ISIN: FR0000120578

SAN: Vaccines, Medicines, Skincare, Pain Relievers, Diabetes Treatments, Oncology Drugs

Sanofi SA is a global healthcare company that focuses on researching, developing, manufacturing, and marketing a wide range of therapeutic solutions. The company operates through three main segments: Pharmaceuticals, Vaccines, and Consumer Healthcare, catering to diverse patient needs across the United States, Europe, Canada, and international markets.

Sanofi's Pharmaceuticals segment offers specialty care solutions, including DUPIXENT, a treatment for moderate-to-severe atopic dermatitis, as well as medicines for neurology and immunology, rare diseases, oncology, and rare blood disorders. The company also provides treatments for diabetes and cardiovascular diseases, along with established prescription products.

The Vaccines segment develops and commercializes a broad portfolio of vaccines, including pediatric vaccines for poliomyelitis, pertussis, and hib, as well as influenza, booster, meningitis, and travel and endemic vaccines. This includes vaccines for hepatitis A, typhoid, cholera, yellow fever, and rabies.

Sanofi's Consumer Healthcare segment offers a range of products for cough, cold, and flu, allergy, and pain care, as well as physical, mental, and digestive wellness products. The company also provides skincare products for various needs, including itching, hydration, aging, cracking, overnight, and specialty skincare for conditions like eczema.

Sanofi has established various collaborations and agreements with other companies to drive innovation and development in the healthcare industry. These partnerships include agreements with Exscientia, ABL Bio, Blackstone Life Sciences, Seagen Inc., IGM Biosciences, Skyhawk Therapeutics, Adagene Inc., Scribe Therapeutics, and Provention Bio, among others. These collaborations focus on developing novel small-molecule therapies, antibody-drug conjugates, and genome editing technologies, among other areas.

Founded in 1994, Sanofi was previously known as Sanofi-Aventis before changing its name in May 2011. The company is headquartered in Paris, France, and is committed to improving the lives of patients worldwide through its innovative healthcare solutions. For more information, visit their website at https://www.sanofi.com.

Additional Sources for SAN Stock

Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

SAN Stock Overview

Market Cap in USD 125,317m
Sector Healthcare
Industry Drug Manufacturers - General
GiC Industry Pharmaceuticals
TER 0.00%
IPO / Inception

SAN Stock Ratings

Growth 5y 51.6%
Fundamental 52.8%
Dividend 66.6%
Rel. Performance Sector -0.16
Analysts -
Fair Price Momentum 87.59 EUR
Fair Price DCF 84.27 EUR

SAN Dividends

Dividend Yield 12m 4.10%
Yield on Cost 5y 5.45%
Annual Growth 5y 3.01%
Payout Consistency 98.73%

SAN Growth Ratios

Growth Correlation 3m -96%
Growth Correlation 12m 78.4%
Growth Correlation 5y 81.5%
CAGR 5y 5.72%
CAGR/Mean DD 5y 0.68
Sharpe Ratio 12m 0.31
Alpha -5.39
Beta 0.33
Volatility 18.35%
Current Volume 1378.4k
Average Volume 20d 1565.3k
What is the price of SAN stocks?
As of December 04, 2024, the stock is trading at EUR 91.67 with a total of 1,378,404 shares traded.
Over the past week, the price has changed by +1.66%, over one month by -8.40%, over three months by -8.35% and over the past year by +10.98%.
Is Sanofi SA a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, Sanofi SA (PA:SAN) is currently (December 2024) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 52.83 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SAN as of December 2024 is 87.59. This means that SAN is currently overvalued and has a potential downside of -4.45%.
Is SAN a buy, sell or hold?
Sanofi SA has no consensus analysts rating.
What are the forecast for SAN stock price target?
According to ValueRays Forecast Model, SAN Sanofi SA will be worth about 94.9 in December 2025. The stock is currently trading at 91.67. This means that the stock has a potential upside of +3.49%.
Issuer Forecast Upside
Wallstreet Target Price 114.1 24.5%
Analysts Target Price - -
ValueRay Target Price 94.9 3.5%